SCHEMBL4891818

SCHEMBL4891818

CC(C)(C)C(=O)OCOC(=O)c1ccc(-c2cn(Cc3ccccc3)c(=O)n2Cc2ccc(C(F)(F)P(=O)(O)OCOC(=O)C(C)(C)C)c(Br)c2)cc1

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 1/20 0.33
PTPN1 P18031 3/20 0.33
PTPN2 P17706 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HDAC6 Q9UBN7 2/20 0.32
RXRA P19793 1/20 0.31
HTR4 Q13639 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPK10 P53779 1/20 0.31
ENO1 P06733 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
MAPK8 P45983 1/20 0.30
PTPRC P08575 1/20 0.30
GCGR P47871 1/20 0.30
BTN3A1 O00481 1/20 0.30
ELANE P08246 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898670 0.99 F2RL3 (0.33) F2RL3PTPN1PTPN2L3MBTL1HDAC6
SCHEMBL4898644 0.90 PTPN1 (0.31) PTPN1PTPN2GCGRBTN3A1
SCHEMBL14257179 0.89 AR (0.34) PTPN1PTPN2L3MBTL1HDAC6ALDH1A1
SCHEMBL14257198 0.89 PTPN1 (0.36) PTPN1PTPN2L3MBTL1MAPK10MAPK8
SCHEMBL4901576 0.84 F2RL3 (0.43) F2RL3PTPN1PTPN2L3MBTL1MAPK10
SCHEMBL14257181 0.84 AR (0.34) L3MBTL1HDAC6ALDH1A1ENO1HDAC1
SCHEMBL4898662 0.83 NOTUM (0.33) PTPN2L3MBTL1HDAC6ALDH1A1MAPK10
SCHEMBL4903704 0.83 MAPK10 (0.42) PTPN1PTPN2L3MBTL1ALDH1A1MAPK10
SCHEMBL4901328 0.83 MAPK10 (0.42) PTPN1PTPN2L3MBTL1ALDH1A1MAPK10
SCHEMBL4956394 0.82 PTPN1 (0.31) PTPN1PTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US claimed
WO-2006078698-A1 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-07-27 WO claimed
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases PPM1B, PPM1D, PTPRS F2RL3 4655/4885PTPN1 13/4885PTPN2 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.